Alpha-2 agonists: Difference between revisions
ClaireLewis (talk | contribs) |
Elcatracho (talk | contribs) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Central | *Central α agonists lower blood pressure by stimulating α-receptors in the brain which causes peripheral vasodilation | ||
==Medications== | ==Medications== | ||
* [[clonidine]] | *[[clonidine]] | ||
* [[guanabenz]] | *[[dexmedetomidine]] | ||
* [[guanfacine]] | *[[guanabenz]] | ||
* [[methyldopa]] | *[[guanfacine]] | ||
* [[moxonidine]] | *[[methyldopa]] | ||
*[[moxonidine]] | |||
*[[Xylazine toxicity|Xylazine]] (veterinary med, drug of abuse) | |||
==Adverse effects== | ==Adverse effects== | ||
Latest revision as of 16:54, 29 November 2020
Background
- Central α agonists lower blood pressure by stimulating α-receptors in the brain which causes peripheral vasodilation
Medications
- clonidine
- dexmedetomidine
- guanabenz
- guanfacine
- methyldopa
- moxonidine
- Xylazine (veterinary med, drug of abuse)
Adverse effects
- sedation
- drying of the nasal mucosa
- rebound hypertension